Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results

被引：0
|
作者：
Bardia, A.
Diamond, J. R.
Mayer, I. A.
Isakoff, S. J.
Abramson, V.
Starodub, A. N.
O'Shaughnessy, J.
Kalinsky, K.
Moroose, R.
Shah, N.
Juric, D.
Shapiro, G. I.
Guarino, M.
Ocean, A. J.
Messersmith, W. A.
Berlin, J. D.
Wegener, W. A.
Sharkey, R. M.
Goldenberg, D. M.
Vahdat, L. T.
机构：
[1] Massachusetts Gen Hosp, Harvard Med Sch, Ctr Canc, Boston, MA 02114 USA
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] Indiana Univ, Hlth Ctr Canc Care, Goshen, IN USA
[5] Texas Oncol Sammons Canc Ctr, Dallas, TX USA
[6] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA
[7] Univ Florida, Hlth Canc Ctr, Orlando, FL USA
[8] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA 02115 USA
[9] Helen F Graham Canc Ctr, Newark, DE USA
[10] Weill Cornell Med, New York, NY USA
[11] Immunomed Inc, Morris Plains, NJ USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P4-22-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-22-15
引用
收藏
页数：3
相关论文
共 50 条
  • [31] SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results
    Starodub, Alexander N.
    Ocean, Allyson J.
    Shah, Manish A.
    Vahdat, Linda T.
    Chuang, Ellen
    Guarino, Michael J.
    Picozzi, Vincent J.
    Thomas, Sajeve S.
    Maliakal, Pius P.
    Govindan, Serengulam V.
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2014, 74 (19)
  • [32] Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience
    Starodub, Alexander
    Ocean, Allyson J.
    Messersmith, Wells A.
    Picozzi, Vincent J.
    Guarino, Michael J.
    Bardia, Aditya
    Thomas, Sajeve Samuel
    Berlin, Jordan
    Shah, Manish A.
    Maliakal, Pius P.
    Wegener, William A.
    Sharkey, Robert M.
    Wilhelm, Francois
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ≥3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC)
    Kalinsky, K.
    Isakoff, S. J.
    Tolaney, S. M.
    Juric, D.
    Mayer, I. A.
    Vahdat, L. T.
    Diamond, J. R.
    O'Shaughnessy, J.
    Moroose, R. L.
    Santin, A. D.
    Shah, N. C.
    Abramson, V.
    Goldenberg, D. M.
    Sharkey, R. M.
    Washkowitz, S. A.
    Wegener, W. A.
    Iannone, R.
    Bardia, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [34] New Perspectives in metastatic triple-negative Breast Cancer Approval of the first-in-class Antibody-Drug Conjugate Sacituzumab Govitecan
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (03) : 142 - 142
  • [35] Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results
    Seneviratne, Lasika C.
    Harnden, Kathleen Kiernan
    Blau, Sibel
    Danso, Michael A.
    Berz, David
    Guaqueta, Delia Constanza
    Schwerkoske, John F.
    O'Shaughnessy, Joyce
    Patt, Debra A.
    Bardia, Aditya
    McCann, Kelly Elizabeth
    Beelen, Andrew Paul
    Zhang, Jingshan
    Yi, John S.
    Hurvitz, Sara A.
    Mardones, Mabel Alejandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR)
    Spring, Laura M.
    Tolaney, Sara M.
    Desai, Neelam
    Comander, Amy
    Mulvey, Therese
    Krop, Ian E.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Ellisen, Leif W.
    Bardia, Aditya
    CANCER RESEARCH, 2021, 81 (04)
  • [37] Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer
    Bardia, A.
    Spring, L. M.
    Juric, D.
    Partridge, A.
    Ligibel, J.
    Kuter, I.
    Peppercorn, J.
    Parsons, H.
    Ryan, P.
    Chawla, D.
    Attaya, V.
    Fitzgerald, D. M.
    Viscosi, E.
    Lormill, B.
    Shellock, M.
    Moy, B.
    Tolaney, S. M.
    Ellisen, L. W.
    ANNALS OF ONCOLOGY, 2020, 31 : S394 - S394
  • [38] Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
    Cardillo, Thomas M.
    Mostafa, Ali A.
    Rossi, Diane L.
    Liu, Donglin
    Chang, Chien-Hsing
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2017, 77
  • [39] Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
    Spring, Laura
    Tolaney, Sara M.
    Desai, Neelam Vijay
    Fell, Geoffrey
    Trippa, Lorenzo
    Comander, Amy H.
    Mulvey, Therese Marie
    McLaughlin, Shannon
    Ryan, Phoebe
    Rosenstock, Aron S.
    Garrido-Castro, Ana Christina
    Lynce, Filipa
    Moy, Beverly
    Isakoff, Steven J.
    Tung, Nadine M.
    Mittendorf, Elizabeth A.
    Ellisen, Leif W.
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
    Chang, Chien-Hsing
    Wang, Yang
    Zalath, Maria
    Liu, Donglin
    Cardillo, Thomas M.
    Goldenberg, David M.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (08) : 1910 - 1919
12345